The undesirable reactions presented below are listed in accordance with the damage to organs and organ systems and frequency of occurrence. Frequency of occurrence is defined as follows: Often (≥1/10), often (≥1 / 100 and <1/10), infrequently (≥1 / 1,000 and <1/100), rarely (≥1 / 10,000 and <1/1 000), rarely (<1/10 000). The following are undesirable reactions,Both with the use of a combination of isotretinoin and erythromycin, and with the use of these active substances separately.
Clinical Trials Data
Disturbances from the skin and subcutaneous tissues
Very often: rashes, dryness, erythema, peeling, burning sensation and itching, skin irritation.
General disorders and disorders at the site of administration
Very often: pain.
Often: reactions at the site of application, including eczema, exfoliative dermatitis and dry skin.
Post-registration data
In addition to unwanted reactions registered during clinical trials, the following adverse reactions were reported during the post-marketing period.
Immune system disorders
Rarely: an allergic reaction.
Disorders from the gastrointestinal tract
Rarely: a feeling of discomfort in the abdomen, pain in the upper departments of the abdomen, diarrhea. Impaired skin and subcutaneous tissue
Rarely: photosensitization, discoloration of the skin, hyperpigmentation of the skin, hypopigmentation of the skin, urticaria.
General disorders and disorders at the site of administration
Rarely: swelling of the face.
If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.